SCHEMBL4288249

SCHEMBL4288249

Fc1cccc(C[C@@H]2CN(Cc3ccccc3)CCN2)c1

nearest known ligand 0.52

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
LTA4H P09960 1/20 0.52
MLNR O43193 2/20 0.47
ALDH1A1 P00352 3/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
TACR1 P25103 1/20 0.46
SIGMAR1 Q99720 3/20 0.46
MEN1 O00255 1/20 0.45
KMT2A Q03164 1/20 0.45
KDM4E B2RXH2 1/20 0.42
HPGD P15428 1/20 0.42
CCR5 P51681 1/20 0.42
PLG P00747 1/20 0.42
BCHE P06276 1/20 0.42
ACHE P22303 1/20 0.42
BACE1 P56817 1/20 0.42
DRD2 P14416 1/20 0.42
DRD4 P21917 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4284512 0.91 LTA4H (0.53) LTA4HMLNRTACR1SIGMAR1BCHE
SCHEMBL27573513 0.87 LTA4H (0.57) LTA4HTACR1SIGMAR1BCHEACHE
SCHEMBL3493484 0.87 LTA4H (0.57) LTA4HTACR1SIGMAR1BCHEACHE
SCHEMBL3491795 0.86 LTA4H (0.61) LTA4HALDH1A1TACR1SIGMAR1BCHE
SCHEMBL24350 0.86 LTA4H (0.61) LTA4HALDH1A1TACR1SIGMAR1BCHE
SCHEMBL18325 0.86 LTA4H (0.61) LTA4HALDH1A1TACR1SIGMAR1BCHE
SCHEMBL4289658 0.86 LTA4H (0.54) LTA4HMLNRALDH1A1TACR1SIGMAR1
SCHEMBL25404067 0.85 LTA4H (0.52) LTA4HSMN1; SMN2TACR1SIGMAR1KMT2A
SCHEMBL4289527 0.84 TACR1 (0.59) LTA4HMLNRALDH1A1TACR1SIGMAR1
SCHEMBL8122330 0.84 LTA4H (0.49) LTA4HALDH1A1TACR1SIGMAR1BACE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090227560-A1 Substituted imidazole compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-09-10 US disclosed
US-20090227560-A1 Substituted imidazole compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-09-10 US disclosed
US-20090227560-A1 Substituted imidazole compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-09-10 US disclosed
US-20090156612-A1 Substituted imidazole compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-06-18 US disclosed
US-20090156612-A1 Substituted imidazole compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-06-18 US disclosed
US-20090156612-A1 Substituted imidazole compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-06-18 US disclosed
WO-2008139941-A1 SUBSTITUTED IMIDAZOLE COMPOUND AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-11-20 WO disclosed
WO-2008139941-A1 SUBSTITUTED IMIDAZOLE COMPOUND AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-11-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090156612-A1 Substituted imidazole compound and use thereof REN, ACE, AGT LTA4H 1197/4885MLNR 539/4885ALDH1A1 388/4885
US-20090227560-A1 Substituted imidazole compound and use thereof REN, ACE, AGT LTA4H 1197/4885MLNR 539/4885ALDH1A1 388/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.